Literature DB >> 15534250

Correlating phenotype and genotype in the periodic paralyses.

T M Miller1, M R Dias da Silva, H A Miller, H Kwiecinski, J R Mendell, R Tawil, P McManis, R C Griggs, C Angelini, S Servidei, J Petajan, M C Dalakas, L P W Ranum, Y H Fu, L J Ptácek.   

Abstract

BACKGROUND: Periodic paralyses and paramyotonia congenita are rare disorders causing disabling weakness and myotonia. Mutations in sodium, calcium, and potassium channels have been recognized as causing disease.
OBJECTIVE: To analyze the clinical phenotype of patients with and without discernible genotype and to identify other mutations in ion channel genes associated with disease.
METHODS: The authors have reviewed clinical data in patients with a diagnosis of hypokalemic periodic paralysis (56 kindreds, 71 patients), hyperkalemic periodic paralysis (47 kindreds, 99 patients), and paramyotonia congenita (24 kindreds, 56 patients). For those patients without one of the classically known mutations, the authors analyzed the entire coding region of the SCN4A, KCNE3, and KCNJ2 genes and portions of the coding region of the CACNA1S gene in order to identify new mutations.
RESULTS: Mutations were identified in approximately two thirds of kindreds with periodic paralysis or paramyotonia congenita. The authors found differences between the disorders and between those with and without identified mutations in terms of age at onset, frequency of attacks, duration of attacks, fixed proximal weakness, precipitants of attacks, myotonia, electrophysiologic studies, serum potassium levels, muscle biopsy, response to potassium administration, and response to treatment with acetazolamide.
CONCLUSIONS: Hypokalemic periodic paralysis, hyperkalemic periodic paralysis, and paramyotonia congenita may be distinguished based on clinical data. This series of 226 patients (127 kindreds) confirms some clinical features of this disorder with notable exceptions: In this series, patients without mutations had a less typical clinical presentation including an older age at onset, no changes in diet as a precipitant, and absence of vacuolar myopathy on muscle biopsy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15534250     DOI: 10.1212/01.wnl.0000143383.91137.00

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  67 in total

Review 1.  Inherited disorders of voltage-gated sodium channels.

Authors:  Alfred L George
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

2.  N1366S mutation of human skeletal muscle sodium channel causes paramyotonia congenita.

Authors:  Qing Ke; Jia Ye; Siyang Tang; Jin Wang; Benyan Luo; Fang Ji; Xu Zhang; Ye Yu; Xiaoyang Cheng; Yuezhou Li
Journal:  J Physiol       Date:  2017-10-15       Impact factor: 5.182

Review 3.  Guidelines on clinical presentation and management of nondystrophic myotonias.

Authors:  Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2020-05-27       Impact factor: 3.217

4.  Treatment and management of neuromuscular channelopathies.

Authors:  Lydia Sharp; Jaya R Trivedi
Journal:  Curr Treat Options Neurol       Date:  2014-10       Impact factor: 3.598

5.  Gene analysis of the calcium channel 1 subunit and clinical studies for two patients with hypokalemic periodic paralysis.

Authors:  K Kageyama; K Terui; S Tsutaya; E Matsuda; M Shoji; S Sakihara; T Nigawara; S Takayasu; T Moriyama; M Yasujima; T Suda
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

6.  Exploring the utility of whole-exome sequencing as a diagnostic tool in a child with atypical episodic muscle weakness.

Authors:  Neil A Hanchard; David R Murdock; Pilar L Magoulas; Matthew Bainbridge; Donna Muzny; YuanQing Wu; Min Wang; James R Lupski; Richard A Gibbs; Chester W Brown
Journal:  Clin Genet       Date:  2012-09-11       Impact factor: 4.438

7.  Multi-minicore disease and atypical periodic paralysis associated with novel mutations in the skeletal muscle ryanodine receptor (RYR1) gene.

Authors:  Haiyan Zhou; Suzanne Lillis; Ryan E Loy; Farshid Ghassemi; Michael R Rose; Fiona Norwood; Kerry Mills; Safa Al-Sarraj; Russell J M Lane; Lucy Feng; Emma Matthews; Caroline A Sewry; Stephen Abbs; Stefan Buk; Michael Hanna; Susan Treves; Robert T Dirksen; Gerhard Meissner; Francesco Muntoni; Heinz Jungbluth
Journal:  Neuromuscul Disord       Date:  2010-01-18       Impact factor: 4.296

8.  Nondystrophic myotonia: challenges and future directions.

Authors:  Jaya R Trivedi; Stephen C Cannon; Robert C Griggs
Journal:  Exp Neurol       Date:  2013-12-18       Impact factor: 5.330

9.  Functional analysis of three Nav1.6 mutations causing early infantile epileptic encephalopathy.

Authors:  Laura Solé; Jacy L Wagnon; Michael M Tamkun
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-09-08       Impact factor: 5.187

10.  The role of CACNA1S in predisposition to malignant hyperthermia.

Authors:  Danielle Carpenter; Christopher Ringrose; Vincenzo Leo; Andrew Morris; Rachel L Robinson; P Jane Halsall; Philip M Hopkins; Marie-Anne Shaw
Journal:  BMC Med Genet       Date:  2009-10-13       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.